Head to Head Survey: Ovid Therapeutics (NASDAQ:OVID) & Corcept Therapeutics (NASDAQ:CORT)

Corcept Therapeutics (NASDAQ:CORT) and Ovid Therapeutics (NASDAQ:OVID) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Profitability

This table compares Corcept Therapeutics and Ovid Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Ovid Therapeutics	N/A	-23.64%	-20.52%

Earnings and Valuation

This table compares Corcept Therapeutics and Ovid Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41 million	17.21	$99.65 million	$0.42	288.55
Ovid Therapeutics	$7.25 million	64.92	-$17.41 million	($0.31)	-7.77

Corcept Therapeutics has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Corcept Therapeutics and Ovid Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1	1	5	1	2.75
Ovid Therapeutics	1	0	10	1	2.92

Corcept Therapeutics presently has a consensus target price of $138.17, suggesting a potential upside of 14.01%. Ovid Therapeutics has a consensus target price of $6.12, suggesting a potential upside of 154.15%. Given Ovid Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Ovid Therapeutics is more favorable than Corcept Therapeutics.

Insider and Institutional Ownership

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Ovid Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Corcept Therapeutics has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500.

Summary

Corcept Therapeutics beats Ovid Therapeutics on 10 of the 14 factors compared between the two stocks.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

About Ovid Therapeutics

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.